Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4Q-TAP Block vs TEA in CRS-HIPEC
NCT03359811Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2017
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of liposomal bupivacaine in primary peritoneal cancer (PPC), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2017; status: completed.
02
Drugs
liposomal bupivacaine
03
Conditions
primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03359811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03359811.